Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review.

International journal of biological macromolecules - 31 Dec 2023

Wang Chao, Zhang Yujing, Zhang Tingting, Xu Jiazhen, Yan Saisai, Liang Bing, Xing Dongming

Abstract excerpt

Overexpression of the epidermal growth factor receptor (EGFR) has been linked to several human cancers, including esophageal cancer, pancreatic cancer, anal cancer, breast cancer, and lung cancer, particularly non-small cell lung cancer (NSCLC). Therefore, EGFR has emerged as a critical target for treating solid tumors. Many 1st-, 2nd-, 3rd-, and 4th-generation EGFR single-target inhibitors with clinical efficacy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 37839594
DOI: 10.1016/j.ijbiomac.2023.127440

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review.PMID 37839594Read ↗

Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy.Semantic proximity Read ↗

Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.Semantic proximity Read ↗

Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor.Semantic proximity Read ↗

Epidermal growth factor receptor: pathway, therapies, and pipeline.Semantic proximity Read ↗

Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy.Semantic proximity Read ↗

Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.Semantic proximity Read ↗

Recent advances in drug design of epidermal growth factor receptor inhibitors.Semantic proximity Read ↗

Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.Semantic proximity Read ↗

Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?Semantic proximity Read ↗

The epidermal growth factor receptor pathway: a model for targeted therapy.Semantic proximity Read ↗

Epidermal growth factor receptors unveiled: a comprehensive survey on mutations, clinical insights of global inhibitors, and emergence of heterocyclic derivatives as EGFR inhibitors.Semantic proximity Read ↗

Therapeutic targeting of the epidermal growth factor receptor in human cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.